News – Page 264 – Endpoints News

SUBSCRIBE

Ex-Biogen exec Steve Holtzman hears the call of Third Rock’s ambitious Decibel

4 years ago

In a stunner, FDA immediately drops its hold on Juno’s lead CAR-T

4 years ago

FDA experts unanimously endorse Amgen’s biosimilar of AbbVie’s $14B franchise drug

4 years ago

Merck triggers a new round of layoffs in R&D reorganization, pushing more jobs into Cambridge, San Francisco

4 years ago

Sage claims another big win on a small study, this time for postpartum depression

4 years ago

$42M in, Flagship startups merge into one immuno-microbiome platform with multiple targets

4 years ago

Shire gains a delayed FDA OK for ‘blockbuster’ dry eye drug lifitegrast

4 years ago

CytRx concedes that its only drug flunked a PhIII sarcoma test, routing shares

4 years ago

Knock it off: Biosimilars are not a 'knockoff' drug

4 years ago

Periscope: Ex-Baxalta exec David Meek takes Paris-based helm for Ipsen

4 years ago

I/O enthusiast Servier signs up for an $807M, second wave PD-1 development deal with Sorrento

4 years ago

Sucampo shutters development effort after lead drug flops in back-to-back studies

4 years ago

FDA offers Novartis a thumbs-up on Enbrel biosimilar as Amgen plays offense/defense simultaneously

4 years ago

Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono

4 years ago

Juno scrambles to avoid being crushed by a hold, but experts question its best case scenario

4 years ago

Why we need to lower U.S. regulatory barriers around biosimilar approvals now

4 years ago

GlaxoSmithKline cautiously follows Sanofi, ramps up a new project for Zika with the NIH

4 years ago

Amgen tees up a swift approval for a franchise destroyer aimed at AbbVie’s $14B drug Humira

4 years ago

Juno’s lead CAR-T slammed with a clinical hold in the last lap ahead of FDA filing

4 years ago

New U.K. translational research effort will test if ketamine can halt alcoholism

4 years ago

Master dealmaker? Medivation CEO David Hung’s overzealous PARP assault falls flat

4 years ago

KaloBios binds up Martin Shkreli and cages his stock in a long goodbye

4 years ago

AbbVie preps franchise decision after Ablynx’s IL-6 drug goes head-to-head against Actemra

4 years ago

Stalled at the FDA, Amicus adds a preclinical rare disease drug in back-ended $90M deal

4 years ago

First page Previous page 261 262 263264265 266 267 Next page Last page